ArticleClinical cancer research : an official journal of the American Association for Cancer Research2016

MAPK Activation Predicts Poor Outcome and the MEK Inhibitor, Selumetinib, Reverses Antiestrogen Resistance in ER-Positive High-Grade Serous Ovarian Cancer.

Karina E Hew et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.